What is the recommended guideline‑directed medical therapy for a patient with mildly reduced left ventricular ejection fraction (40‑45 %) and the following echocardiographic findings: moderate concentric left ventricular hypertrophy, inferior and inferolateral wall hypokinesis, Grade I diastolic dysfunction, severely dilated left atrium, calcific aortic valve without stenosis or regurgitation, mild mitral stenosis and regurgitation, and trace tricuspid regurgitation?

Guideline-Directed Medical Therapy for Mildly Reduced LVEF (40-45%)

This patient with LVEF 40-45% should receive quadruple foundational therapy consisting of: (1) ACE inhibitor or ARB (or preferably sacubitril/valsartan if tolerated), (2) evidence-based beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), (3) mineralocorticoid receptor antagonist (spironolactone or eplerenone), and (4) SGLT2 inhibitor (dapagliflozin or empagliflozin), plus diuretics as needed for congestion management.

Core Pharmacotherapy Framework

Four Pillars of Disease-Modifying Therapy

The 2022 AHA/ACC/HFSA guidelines establish that patients with LVEF 40-45% (classified as heart failure with mildly reduced ejection fraction, HFmrEF) should receive the same foundational therapies as those with more severely reduced ejection fraction 1, 2, 3. This represents a critical shift from older paradigms that reserved these therapies primarily for LVEF <40%.

1. Renin-Angiotensin System Inhibition (Class I)

• ACE inhibitors should be started and continued indefinitely in all patients with LVEF ≤40% 4, 5
• Sacubitril/valsartan (ARNI) is preferred over ACE inhibitors when tolerated, as it provides superior mortality and hospitalization reduction 1, 2
• Start sacubitril/valsartan at low dose (24/26 mg or 49/51 mg twice daily) and uptitrate to target 97/103 mg twice daily 6
• If ACE inhibitor intolerant, use ARB as alternative 4, 5
• In patients with low blood pressure, start with very low dose sacubitril/valsartan (25 mg twice daily) or low-dose ACE inhibitor first 7

2. Evidence-Based Beta-Blockers (Class I)

• Use only carvedilol, metoprolol succinate, or bisoprolol—these are the three beta-blockers proven to reduce mortality 4, 5, 2
• Beta-blocker therapy should be used in all patients with left ventricular systolic dysfunction (EF ≤40%) with heart failure 4, 5
• Initiate at low dose and uptitrate to target doses used in clinical trials 6
• In low blood pressure scenarios, selective β₁ receptor blockers (metoprolol, bisoprolol) may be preferred over non-selective agents due to lesser BP-lowering effect 7
• If beta-blockers not tolerated due to hypotension and patient in sinus rhythm with HR >70 bpm, ivabradine may be used as alternative or adjunct 7

3. Mineralocorticoid Receptor Antagonists (Class I)

• Spironolactone or eplerenone are recommended in all symptomatic patients with HFrEF and LVEF ≤35% despite treatment with ACE inhibitor and beta-blocker 6
• For LVEF 40-45%, MRAs should be considered, particularly in patients with diabetes or prior heart failure hospitalization 4, 5
• Critical safety monitoring: Check serum potassium and renal function regularly; avoid if potassium >5.0 mmol/L or significant renal dysfunction 6
• MRAs do not significantly lower blood pressure, making them suitable for early initiation even in hypotensive patients 7

4. SGLT2 Inhibitors (Class I)

• Dapagliflozin or empagliflozin should be initiated regardless of diabetes status to reduce mortality and hospitalization 1, 2, 8
• Benefits emerge within weeks of initiation 9
• SGLT2 inhibitors do not lower blood pressure significantly, allowing early initiation alongside other therapies 7
• This represents one of the most important recent advances in HF therapy, with consistent benefits across the LVEF spectrum >40% 10, 11

Sequencing and Initiation Strategy

Rapid Implementation Approach

"Four drugs in 4 weeks" protocol 9:

• Week 1: Initiate SGLT2 inhibitor and MRA (neither significantly lowers BP)
• Week 2: Add low-dose beta-blocker if HR >70 bpm OR low-dose ACE inhibitor/ARB/sacubitril-valsartan
• Week 3-4: Add the remaining foundational drug class
• Uptitrate one drug at a time every 1-2 weeks using small increments 7

In patients with low blood pressure (<90 mmHg systolic), modify sequence 7:

• Start with SGLT2 inhibitor and MRA first (minimal BP effect)
• Then add either low-dose beta-blocker (if HR >70 bpm) or very low-dose sacubitril/valsartan (25 mg twice daily)
• Monitor closely and uptitrate gradually
• Consider selective β₁ blockers over non-selective agents

Diuretic Management

Loop diuretics are recommended to reduce signs and symptoms of congestion 6:

• Aim for euvolemia with lowest achievable dose
• Adjust dose according to individual needs over time
• In selected asymptomatic euvolemic patients, diuretics may be temporarily discontinued 6
• Patients can be trained to self-adjust diuretic dose based on symptoms/signs
• Overdiuresis can worsen hypotension and should be avoided 7

Additional Considerations for This Patient's Specific Findings

Valvular Disease Management

Mild mitral stenosis and regurgitation:

• Does not contraindicate standard HF therapy
• Monitor for progression
• Severe mitral stenosis would require specific intervention, but mild disease as described does not alter medical management 12, 13

Calcific aortic valve without stenosis or regurgitation:

• Monitor for progression to aortic stenosis
• Does not alter current HF pharmacotherapy 13, 14

Atrial Enlargement

Severely dilated left atrium:

• Increases risk of atrial fibrillation
• If AF develops, consider anticoagulation based on CHA₂DS₂-VASc score
• Beta-blockers particularly important for rate control if AF occurs 6
• Does not change foundational HF therapy recommendations

Regional Wall Motion Abnormalities

Inferior and inferolateral hypokinesis:

• Suggests possible ischemic etiology
• Consider evaluation for coronary artery disease if not already done
• Revascularization may be considered if significant ischemia demonstrated 1
• Does not alter medical therapy recommendations

Target Doses and Monitoring

Uptitration targets (from clinical trials):

• Sacubitril/valsartan: 97/103 mg twice daily
• Enalapril equivalent: 10 mg twice daily
• Carvedilol: 25-50 mg twice daily
• Metoprolol succinate: 200 mg daily
• Bisoprolol: 10 mg daily
• Spironolactone: 25-50 mg daily
• Eplerenone: 50 mg daily

Monitoring parameters:

• Blood pressure at each visit
• Heart rate at each visit
• Serum potassium and creatinine every 1-2 weeks during uptitration, then every 3-6 months
• Symptoms and functional capacity
• Volume status (weight, edema, orthopnea)

Common Pitfalls to Avoid

1. Delaying therapy initiation because LVEF is "only" 40-45%—this population benefits from the same therapies as more severe HFrEF 15, 16

2. Sequential rather than simultaneous initiation—all four drug classes should be started within weeks, not months 9

3. Stopping medications due to asymptomatic hypotension—low BP without symptoms does not require dose reduction if patient tolerates therapy 7

4. Inadequate uptitration—target doses from clinical trials should be the goal, not arbitrary "comfortable" doses 17

5. Withholding MRAs due to mild renal dysfunction—can be used cautiously with close monitoring if potassium <5.0 mmol/L 6

6. Assuming valvular disease contraindicates HF therapy—mild mitral disease does not alter medical management 12